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ABSTRACT
Introduction Type 1 diabetes is heterogeneous in 
its presentation and progression. Variations in clinical 
presentation between children and adults, and with 
ethnic group warrant further study in the UK to improve 
understanding of this heterogeneity. Early interventions to 
limit beta cell damage in type 1 diabetes are undergoing 
evaluation, but recruitment is challenging. The protocol 
presented describes recruitment of people with clinician-
assigned, new-onset type 1 diabetes to understand 
the variation in their manner of clinical presentation, to 
facilitate recruitment into intervention studies and to 
create an open-access resource of data and biological 
samples for future type 1 diabetes research.
Methods and analysis Using the National Institute for 
Health Research Clinical Research Network, patients >5 
years of age diagnosed clinically with type 1 diabetes (and 
their siblings) are recruited within 6 months of diagnosis. 
Participants agree to have their clinical, laboratory and 
demographic data stored on a secure database, for their 
clinical progress to be monitored using information held by 
NHS Digital, and to be contacted about additional research, 
in particular immunotherapy and other interventions. 
An optional blood sample is taken for islet autoantibody 
measurement and storage of blood and DNA for future 
analyses. Data will be analysed statistically to describe the 
presentation of incident type 1 diabetes in a contemporary 
UK population.
Ethics and dissemination Ethical approval was obtained 
from the independent NHS Research Ethics Service. 
Results will be presented at national and international 
meetings and submitted for publication to peer-reviewed 
journals.
IntroductIon
Type 1 diabetes (T1D) is the most common 
form of diabetes in childhood, but it is 
frequently diagnosed in adults.1 In the UK 
it is most common in people of white Euro-
pean descent, but also affects other ethnic 
groups,2 and it is heterogeneous in initial 
clinical presentation and in its progression.3 
Markers of autoimmunity, such as antibodies 
to islet antigens, most commonly glutamate 
decarboxylase (GADA), insulin itself, islet 
antigen 2 (IA-2A) and zinc transporter-T8 
(ZnT-8A), are frequently, but not always 
detectable at onset in people with a clinical 
diagnosis of T1D.4–6 Measurement of autoan-
tibodies is advocated by many to aid diabetes 
classification,3 7–9 but only recommended in 
the UK when knowledge of autoantibody 
status (positive/negative) would have impli-
cations for clinical management or access 
to treatment (eg, ‘insulin pump’ therapy).10 
Few T1D cohorts include both children and 
adults and, where studied, clinical charac-
teristics and autoantibody frequencies have 
been found to vary between children and 
adults at onset.11–15 Additionally, descriptions 
of adult-onset diabetes with autoantibodies 
have highlighted differences in T1D pheno-
type at onset between adults and children.16 17 
Reports of the variation of autoantibody status 
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Protocol
Strengths and limitations of this study
 ► Children and adults (including older adults) are 
characterised soon after disease onset.
 ► There is wide geographical spread of ascertainment.
 ► The study allows differences in presentation of type 
1 diabetes to be assessed by ethnic group.
 ► There is no attempt to capture information on all 
incident cases.
 ► Assessment of C-peptide and genetic risk markers is 
desirable in the characterisation of new-onset type 
1 diabetes, but beyond the scope of this protocol. 
However, the  After Diabetes Diagnosis REsearch 
Support System resource will enable precisely such 
future studies.
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and frequency with ethnicity are also scarce and have 
revealed a somewhat conflicting picture.6 18–20 Differences 
in presenting features of T1D with autoantibody status 
warrant further investigation in children and adults in the 
multiethnic UK population to improve understanding of 
the heterogeneity of T1D. People with T1D have a life-
long dependency on treatment with exogenous insulin, 
resulting from an autoimmune destruction of pancreatic 
beta cells. Early intervention therapies are emerging that 
aim to limit this autoimmune destruction and preserve 
beta cell function.21 22 Preservation of even modest 
levels of insulin secretion has been shown to reduce 
the risk of developing diabetic complications, improve 
glycaemic control and may also protect against severe 
hypoglycaemia.23 24 Many investigational therapies target 
new-onset T1D — at a stage when there is still significant 
insulin secretion to preserve. Recruitment to trials in 
new-onset T1D is challenging, in part because individual 
centres see a relatively small number of incident cases per 
year. The aims of the After Diabetes Diagnosis REsearch 
Support System (ADDRESS) are therefore the following:
1. to characterise people with clinician-assigned, new-
onset T1D, demographically, clinically and by islet 
autoantibody status, in a national, multiethnic cohort, 
and to perform hypothesis-generating analyses 
investigating the heterogeneity of clinical presentation
2. to use the cohort of children and adults with incident 
T1D and their siblings to support recruitment into T1D 
trials and other clinical research studies by providing 
them with information about studies for which they 
might be eligible (initially in new-onset T1D, and with 
time, studies in established T1D, or studies for first-
degree relatives), thereby also increasing awareness 
of opportunities to participate in research among 
patients and their families
3. to establish an open-access resource of data and 
biological samples, including DNA, collected close to 
diagnosis for use in other T1D research, forming, in 
particular, a foundation for prospective studies from 
the time of diagnosis.
There are a number of ongoing initiatives in the USA and 
Europe to characterise people with incident T1D, some 
of which include the banking of biological samples and 
open access to samples or data, some that include the 
study of first-degree relatives, and some that also support 
the conduct of clinical trials. Exemplar initiatives are 
summarised in table 1, in comparison with ADDRESS. 
There are T1D registries in the UK primarily set up to 
drive improvements in clinical care, and the notable 
open-access Warren repository,25 established to further 
understanding of T1D genetic susceptibility. There are, 
however, no national, multiethnic collections of data and 
biological samples from both children and adults with 
incident T1D in the UK. The Scottish Health Research 
register SHARE is an example of another national 
resource that supports recruitment to clinical research, 
although unlike ADDRESS it does not focus on new-onset 
T1D.26 The features of these UK-specific T1D registries 
and resources are summarised in table 2.
In 2006 the National Institute for Health Research 
Clinical Research Network (NIHR CRN) was set up as 
the research delivery arm of the National Health Service 
(NHS) in England. The universal health coverage of 
the NHS, coupled with the NIHR CRN, makes the UK a 
particularly suitable environment for studies in new-onset 
T1D. This is further strengthened via linkage with the 
ADDRESS new-onset T1D ascertainment network, which is 
dedicated to identifying people with incident T1D shortly 
after diagnosis and offering them and their siblings entry 
into T1D clinical research studies. ADDRESS is a partner 
in the T1DUK Consortium, formed in 2015 to promote, 
support and develop immunotherapy research in the UK 
via a network of centres to conduct clinical trials, and a 
mechanistic core to conduct state-of-the-art assays to study 
the immunology of T1D and the mechanisms of action of 
immunotherapies.
Methods and analysIs
establishment of the cohort
The After Diabetes Diagnosis REsearch Support System 
(previously referred to as ADDRESS or ADDRESS-2, 
hereafter as ADDRESS) started in pilot form in 2008 to 
establish the ‘proof of concept’ that ascertainment and 
recruitment of people with incident T1D shortly after 
diagnosis were feasible in substantial numbers using the 
resources of the NIHR CRN. Patients with a clinician-as-
signed diagnosis of T1D were recruited if they agreed to 
have their data on a database and to be contacted about 
other research projects for which they might be eligible. 
Clinical and demographic information, including the 
participant’s unique NHS identifier, was obtained for 
analysis, but no biological samples were collected. This 
pilot was established in 78 recruiting hospitals in England 
and Wales. NIHR CRN staff recruited 645 participants 
between 2008 and 2010. With cofunding from Diabetes 
UK and the Juvenile Diabetes Research Foundation, and 
with separate NHS Research Ethics Committee review, 
the project was expanded to its present and ongoing 
form in January 2011 in which 156 hospitals are partic-
ipating in 124 NHS Trusts across England and Health 
Boards in Wales. Figure 1 illustrates the timeline of devel-
opment of ADDRESS, and figure 2 shows the locations 
of centres participating currently. The NIHR CRN struc-
ture provides research support via 15 local branches in 
England and a related system exists to support diabetes 
research in Wales.
Inclusion and exclusion criteria
During the first 3 years of the current study (2011–2014), 
people with a clinician-assigned diagnosis of T1D aged 
5–60 years were recruited within 6 months of diagnosis. 
From October 2014 the upper age limit was removed to 
allow newly diagnosed adults over the age of 60 to partic-
ipate. People initially diagnosed with another diabetes 
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Figure 1 Study timeline.
subtype and later reassigned a diagnosis of T1D are eligible 
if still within 6 months of the initial diagnosis. Adults who 
are not competent to give consent are excluded. People 
who took part in the pilot form of ADDRESS are eligible 
to be recruited to the current study, and their individual 
data are transferred from the pilot into the current study.
sample size
The annual incidence of T1D in the UK is 22–30 per 
100 000 in the 0–14 years age group, with an estimated 
76% of incident cases aged 5–14 years27. There is a paucity 
of incidence data for adults worldwide, but one UK study 
reported an incidence of 12 per 100 000 for those aged 
15–34 years.28 Therefore, we estimate that 3900–4500 chil-
dren and adults will be diagnosed per year in the current 
recruitment age range in England and Wales.
recruitment
Methods vary depending on local resources and prefer-
ences, but local researchers (NIHR CRN research nurses 
and/or other local research nurses and physicians) 
perform the recruitment mainly via secondary care and 
specialist diabetes centres, as patients (both children 
and adults) are mostly seen clinically in these settings. 
Recruiting staff in the NIHR CRN have been trained to 
approach patients and families with sensitivity soon after 
diagnosis and to take informed consent. Permission is 
sought from the patient or parent/guardian to approach 
siblings. The patients, their siblings and the parent/
guardian for children aged 5–15 years are provided 
with age-specific information sheets about the study by 
the local researcher. Informed consent is sought at least 
1 week after diagnosis and at least 48 hours after the infor-
mation sheets have been given. Recruitment support 
initiatives have included providing NHS clinical care 
teams with information about T1D research, displaying 
posters about ADDRESS and providing patients with leaf-
lets introducing clinical research and ADDRESS in clinic 
and in packs for newly diagnosed patients. A website 
provides additional information.
consent
ADDRESS operates a two-tier consent model: for tier 1, 
participants provide written informed consent for their 
health and contact details to be held on a database and 
for their being contacted about studies. They also consent 
to follow-up using information held by NHS Digital and 
the Office for National Statistics (ONS). With additional 
second-tier consent, participants may choose to donate 
blood samples for islet autoantibody analysis and storage 
of blood and DNA for future use in diabetes research.
data collection
At the time of recruitment participant information is 
collected via interview with the participant or parent/
guardian, and from specialist care medical records, as 
shown in table 3. Ethnicity is self-reported as one of 16 cate-
gories, following UK ONS guidance on collecting ethnic 
group data. A diagnosis of parental or grandparental 
diabetes is recorded without subtype because historical 
classifications may be incorrect or incomplete.29 Labora-
tory test results are recorded from those tests performed 
locally as part of routine clinical care. A diagnosis of keto-
acidosis at presentation is recorded if assigned by the 
local clinical team, or if all of the following were docu-
mented in the clinical records: glucose >11 mmol/L; 
blood ketone bodies >3 mmol/L or urine ketones levels 
positive ++; pH <7.3; and/or bicarbonate <15 mmol/L. 
Except for the additional specialist care information avail-
able for patients, similar data are collected at baseline for 
siblings.
Project-specific blood sampling
Sample donation is a voluntary component of ADDRESS, 
currently for participants with T1D only (prior to October 
2014, siblings were also given the option of donating 
samples). Random blood samples are collected and sent 
at ambient temperature via standard post to the Public 
Health England European Collection of Cell Cultures at 
Porton Down, UK, which operates in accordance with the 
UK Human Tissue Act 2004. Serum (from a serum sepa-
ration tube) and peripheral blood lymphocytes (PBLs, 
from an acid citrate dextrose tube) are separated on 
arrival. An EDTA tube is frozen for later DNA extraction 
(median: 2 (IQR: 1–3) days after sampling). The samples 
are stored in coded, pseudoanonymised format and 
include serum from coagulated blood, extracted and 
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Figure 2 Map with circles showing the locations of the 156 recruiting centres in 124 English NHS Trusts and Welsh Health 
Boards (an estimated 84% of the total number that provide acute care services). Numbers of centres recruiting from both 
paediatric and adult clinics, the paediatric clinic only, and the adult clinic only are 80, 32 and 44, respectively.
resuspended DNA, PBLs, and lymphoblastoid cell lines 
(LCLs) derived by Epstein-Barr virus transformation of 
thawed PBLs. Samples are stored at −80°C and PBLs and 
LCLs are placed in liquid nitrogen for cryopreservation 
for the duration of the study. An aliquot (0.5 mL) of 
serum from each blood sample is sent to the University 
of Bristol for autoantibody measurements.
Islet autoantibody measurement
Autoantibodies to GADA, IA-2A and ZnT-8A are 
measured in participants with T1D using established 
radiobinding assays.30 31 Insulin autoantibodies are not 
measured as these people are receiving exogenous 
insulin therapy, which could itself induce an immune 
response.
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Table 3 Data and associated methods of collection for participants with incident T1D and for sibling participants at the time 
of recruitment
Data Incident T1D Sibling
Via interview 
or at visit
Via or validated 
against medical 
records
Via interview 
or at visit
Contact details and unique NHS identifier X X
General practitioner (GP) details (GP is informed of the person’s 
participation)
X X
Diabetes care physician details (physician is informed of the person’s 
participation if not the principal investigator at the research site)
X X
Demographic information including self-reported ethnic origin X X
Date of diagnosis, clinical presentation and duration of symptoms 
(presentation with diabetic ketoacidosis, polyuria/polydipsia, weight loss, 
fatigue, abdominal pain,* fasting or random plasma glucose)
X X
Current diabetes treatment regimen, including date insulin first administered X X
Non-diabetic medication X X X
Medical history including history of autoimmune diseases (Addison’s 
disease, coeliac disease, hyperthyroidism, hypothyroidism and vitiligo) and 
of gestational diabetes
X X X
Family medical history including parental and grandparental history of 
diabetes, hypertension, myocardial infarction and stroke, along with sibling 
demographics and diabetes history
X X
Clinical measures, including blood pressure, weight and height using 
standard protocols
X X
Blood biochemistry including glycated haemoglobin (HbA1c) (mmol/
mol), fasting or random plasma glucose (mmol/L), oral glucose tolerance 
test results (mmol/L) if performed locally and C-peptide levels (nmol/L) if 
performed locally
X
Details of diabetes structured education offered/scheduled/completed* X X
*Collected for participants recruited from February 2015 onwards.
T1D, type 1 diabetes; NHS, National Health Service.
Antigens radiolabelled with 35S methionine are 
expressed using a TNT in vitro reticulocyte lysate quick 
coupled transcription/translation system kit (Promega, 
Madison, Wisconsin, USA) with plasmids encoding full-
length GAD65, the intracytoplasmic region of IA-2 (aa 
606–979), and the 325-arginine (ZnT8R) and 325-trypto-
phan (ZnT8W) isoforms of the C-terminal region of ZnT8 
(aa268-379). Immunocomplexes formed following incu-
bation of sera with radiolabelled antigens are precipitated 
with Protein A-Sepharose (GE Healthcare Life Sciences, 
Little Chalfont, Bucks, UK), washed and counted in a 
TopCount beta counter (PerkinElmer, Waltham, Massa-
chusetts, USA).
Results are expressed in digestive and kidney 
(DK) units/mL (GADA and IA-2A) or arbitrary units 
(ZnT8A) after reference to standard curves consisting of 
dilutions of patient sera in antibody-negative sera from 
healthy donors. Thresholds are set at the 97th percentile 
of 974 control samples for GADA, the 98th percentile of 
500 control samples for IA-2A and the 97.5th percentile of 
523 healthy schoolchildren for ZnT8A. The GADA assay 
achieves a sensitivity of 74% at 96.7% specificity, while the 
IA-2A, ZnT8RA and ZnT8WA assays achieve sensitivities 
of 72%, 60% and 46%, respectively, at 100% specificity, 
in the 2015 Islet Autoantibody Standardization Program 
Workshop. Interassay coefficients of variation of high and 
moderate/low positive samples, respectively, were 18% 
and 18% for GADA, 19% and 17% for IA-2A, 22% and 
16% for ZnT8RA, and 25% and 20% for ZnT8WA.
Follow-up data collection and verification
Participants with T1D are reviewed via their medical 
records at 4–8 months following diagnosis to verify that 
their original clinical diabetes classification has not been 
changed by their clinicians. Data reviewed at the follow-up 
are shown in table 4.
An application to NHS Digital and the UK ONS is 
planned for tracing change of postal address, mortality 
flagging and access to hospital admission data (Hospital 
Episode Statistics).
database
Data are entered into a secure electronic data capture 
and management system designed specifically for clinical 
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Table 4 Data collection for participants with incident T1D 
at 4–8 months postdiagnosis and at least 2 months after the 
time of recruitment
Data Incident T1D
Via medical 
records
Confirmation of, or change in classification 
of, diabetes subtype
X
Occurrence of diabetic ketoacidosis since 
diagnosis*
X
Any change in diabetes treatment or dose, 
and concurrent medication
X
Clinical measures, including blood pressure, 
weight and height
X
Blood biochemistry including glycated 
haemoglobin (HbA1c) (mmol/mol), fasting 
or random plasma glucose (mmol/L), oral 
glucose tolerance test results (mmol/L) 
if performed locally and C-peptide levels 
(nmol/L) if performed locally
X
Details of diabetes structured education 
offered/scheduled/completed*
X
All data are collected from medical records.
*Collected for participants recruited from February 2015 onwards.
T1D, type 1 diabetes.
research. All information is stored in accordance with the 
UK Data Protection Act (1998).
recruitment into other studies
Eligible participants are given information at intervals 
about specific diabetes trials/research studies by the 
central study team or local researchers. Information is 
retained on those previously contacted about research 
and whether or not they are currently participating in a 
study.
data analysis plan
The collected data allow generation and testing of hypoth-
eses about the presentation of clinician-assigned T1D and 
other characteristics early after diagnosis. Our aim is to 
compare characteristics between groups: for example, 
islet autoantibody positive and negative; ethnicity group-
ings of white European, South Asian (including Indian, 
Pakistani and Bangladeshi) and African-Caribbean (black 
African or black Caribbean); and children and adults. 
We aim also to investigate the relationships between 
insulin dose and glycaemic control. Recorded variables 
are categorised as ‘Individual Characteristics’ (eg, age, 
gender, child/adult, birth weight, ethnicity, history of 
other autoimmune disease, parent with diabetes, sibling 
with diabetes), ‘Diabetes Presentation’ (eg, ketoacidosis 
at T1D presentation, osmotic symptoms (polydipsia/
polyuria), weight loss, fatigue, symptom duration, initial 
insulin dose and autoantibody status) and ‘Diabetes 
Characteristics’ (eg, insulin dose, glycated haemoglobin 
(HbA1c) at time points after presentation).
ethIcs and dIsseMInatIon
Ethical approval was obtained from the NHS Research 
Ethics Committee - South Central-Berkshire (refer-
ence 10/H0505/85), and each participating NHS Trust 
submitted a Site-Specific Assessment in order to partic-
ipate. The project is conducted in accordance with the 
recommendations for physicians involved in research 
on human subjects by the 18th World Medical Assembly, 
Helsinki 1964 and later revisions. The International 
Conference on Harmonisation Guideline for Good Clin-
ical Practice (Topic E6 — 10 June 1996) and participant 
confidentiality are maintained throughout.
ADDRESS is an accessible resource for clinical and 
academic researchers, both as an infrastructure to identify 
and contact candidates for recruitment into T1D studies 
and as an open-access database and biological sample 
repository. Access is through a management committee 
comprised of lay people, scientists and clinical inves-
tigators representing relevant T1D research interests. 
Researchers wishing to use the ADDRESS-2 resource can 
apply to the ADDRESS-2 Management Committee. The 
access process and associated documents are described 
on the study website (www. address2. org).
Ethical approval will be sought for continuing use 
of the data every 5 years (current approval is to the 
end of 2019). Every effort will be made to sustain this 
open-access resource beyond the present funding term. 
The database will be maintained by Imperial College 
London. The biological samples will continue to be 
stored for as long as there is funding to support the 
repository.
The results arising from this project will be presented 
at national and international meetings, and submitted 
for publication to peer-reviewed medical journals.
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